Argenx Se (ARGX) AI Stock Analysis

• Market Cap: $51.98B
• Dividend Yield: N/A
• Average Volume (3M): 349.57K
• Price to Earnings (P/E): 38.2
• Beta (1Y): 0.37
• Revenue Growth: 89.58%
• EPS Growth: N/A
• Country: US
• Employees: 1,599
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.74
• Shares Outstanding: 61,568,928
• 10 Day Avg. Volume: 340,079
• 30 Day Avg. Volume: 349,572
• PEG Ratio: -0.12
• Price to Book (P/B): 6.70
• Price to Sales (P/S): 16.81
• P/FCF Ratio: -243.71
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 14.08
• Enterprise Value/Gross Profit: 21.27
• Enterprise Value/Ebitda: 78.04
• 1Y Price Target: $875.11
• Price Target Upside: 7.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23

• Rating: 76 Outperform
• Price Target: $943.00 ▲(15.38% Upside)

Argenx Se's strong financial performance, particularly in revenue growth and profitability, combined with bullish technical indicators and positive earnings call sentiment, contribute to a solid stock score. However, valuation concerns and operational challenges temper the overall outlook.

Positive Factors

Revenue Growth

Argenx's significant revenue growth indicates strong market demand and successful product commercialization, enhancing its competitive position in the biotech industry.

Pipeline Advancements

The development of new molecules and pipeline expansion demonstrates Argenx's commitment to innovation and long-term growth potential in addressing unmet medical needs.

Strong Balance Sheet

Argenx's strong balance sheet with minimal leverage provides financial stability and flexibility to invest in growth opportunities and withstand market fluctuations.

Negative Factors

Operational Efficiency Challenges

Ongoing operational challenges reflected in negative EBIT margins could hinder Argenx's ability to fully capitalize on revenue growth and impact long-term profitability.

Cash Flow Inefficiencies

Inefficiencies in converting income into cash flow may limit Argenx's ability to fund operations and strategic initiatives, posing a risk to sustainable growth.

Increased Gross to Net Adjustments

Higher gross to net adjustments could pressure margins and profitability, affecting Argenx's financial performance and pricing strategy in the long term.

Argenx Se Business Overview & Revenue Model

Company Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

How the Company Makes Money

Argenx generates revenue primarily through the development and commercialization of its therapeutic candidates. Key revenue streams include product sales from approved therapies, milestone payments from partnerships, and royalties from licensed products. The company has established strategic collaborations with major pharmaceutical firms, which provide upfront payments and contingent milestone payments tied to the development and commercialization of its products. Additionally, Argenx may receive royalties based on the future sales of partnered products, contributing to its overall earnings. The successful advancement of its clinical pipeline, especially the commercialization of efgartigimod, plays a pivotal role in its revenue generation strategy.

Argenx Se Financial Statement Overview

Summary

Argenx Se has shown significant revenue growth and improved profitability. The strong balance sheet with minimal leverage provides financial stability. However, challenges in operational efficiency and negative cash flow require attention.

Income Statement

Argenx Se has shown a significant increase in total revenue from 2023 to 2024, with a revenue growth rate of 77.32%. The company has also improved its profitability, turning a net income of $804 million in 2024 from a net loss of $295 million in 2023. However, the EBIT margin remains negative, indicating ongoing operational challenges.

Balance Sheet

The company's balance sheet is strong, with a high equity ratio of 88.64% and a low debt-to-equity ratio of 0.007. This indicates financial stability and low leverage, reducing financial risk. The return on equity has improved significantly due to positive net income, which enhances shareholder value.

Cash Flow

Argenx Se has managed to improve its free cash flow position slightly, but it remains negative. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income into cash flow. However, the company has strong financing activities that continue to support its cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.29B	2.19B	1.23B	410.75M	497.28M	41.24M
Gross Profit	1.52B	1.96B	1.11B	381.31M	497.28M	41.24M
EBITDA	413.96M	105.17M	-192.28M	-622.78M	-392.78M	-601.03M
Net Income	1.11B	833.04M	-295.05M	-709.59M	-407.63M	-608.46M
Balance Sheet
Total Assets	7.18B	6.20B	4.54B	3.13B	2.85B	2.28B
Cash, Cash Equivalents and Short-Term Investments	3.93B	3.38B	3.18B	2.19B	2.34B	2.00B
Total Debt	43.15M	39.05M	20.00M	12.43M	11.46M	9.66M
Total Liabilities	1.08B	704.24M	444.95M	320.56M	316.05M	605.36M
Stockholders Equity	6.10B	5.50B	4.10B	2.81B	2.53B	1.67B
Cash Flow
Free Cash Flow	473.52M	-151.05M	-464.14M	-966.63M	-728.25M	-403.60M
Operating Cash Flow	479.76M	-82.75M	-420.33M	-862.81M	-606.81M	-398.46M
Investing Cash Flow	-214.14M	-717.59M	308.21M	-461.18M	-347.07M	344.69M
Financing Cash Flow	313.76M	279.76M	1.34B	843.76M	1.12B	833.00M

Argenx Se Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 817.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARGX, the sentiment is Positive. The current price of 817.32 is above the 20-day moving average (MA) of 801.93, above the 50-day MA of 751.49, and above the 200-day MA of 640.48, indicating a bullish trend. The MACD of 23.45 indicates Positive momentum. The RSI at 61.02 is Neutral, neither overbought nor oversold. The STOCH value of 33.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARGX.

Argenx Se Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	80 Outperform	$17.05B	20.02	24.30%	―	18.87%	1088.27%
ARGX	76 Outperform	$51.98B	38.25	24.75%	―	89.58%	―
GMAB	74 Outperform	$18.37B	14.79	26.08%	―	23.25%	64.46%
REGN	73 Outperform	$61.98B	14.51	15.34%	0.46%	5.38%	3.58%
ALNY	60 Neutral	$60.82B	―	-257.82%	―	5.01%	-330.09%
BNTX	56 Neutral	$25.54B	―	-1.81%	―	7.51%	30.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Argenx Se Corporate Events

Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting

On October 15, 2025, Argenx SE announced its participation in the 2025 AANEM Annual Meeting and MGFA Scientific Session, where it will present pivotal data on VYVGART and empasiprubart. The company highlighted the potential of VYVGART in treating myasthenia gravis and other neuromuscular diseases, showcasing results from various studies that demonstrate its efficacy and safety. This presentation underscores Argenx’s commitment to advancing innovative therapies and improving patient outcomes in the field of autoimmune and neuromuscular diseases.

Argenx SE Calls Extraordinary Shareholder Meeting for November 2025

On October 3, 2025, Argenx SE announced that it will hold an Extraordinary General Meeting of Shareholders on November 18, 2025, in Amsterdam. The meeting will address the adoption of a revised remuneration policy, and shareholders are encouraged to participate via electronic proxy voting. This meeting is significant for stakeholders as it may impact the company’s governance and strategic direction.

argenx Reports Positive Results from ADAPT SERON Study for VYVGART

On August 25, 2025, argenx announced positive topline results from its ADAPT SERON study of VYVGART in patients with AChR-Ab seronegative gMG. The study met its primary endpoint, showing significant improvement in patients’ MG-ADL scores, and demonstrated VYVGART’s potential as a targeted treatment across all AChR-Ab seronegative subtypes. The company plans to submit a supplemental Biologics License Application to the FDA by the end of 2025, aiming to expand VYVGART’s label to include these patient subtypes. This advancement highlights argenx’s commitment to addressing the unmet needs of the MG community and could significantly impact its industry positioning.

Argenx SE Reports Robust Second Quarter 2025 Financial Results and Strategic Advancements

On July 31, 2025, Argenx SE announced its unaudited financial results for the first half of 2025, reporting $949 million in global product net sales for the second quarter. The company is advancing its Vision 2030 strategy, aiming to treat 50,000 patients globally and secure 10 labeled indications by 2030. Recent developments include the successful launch of VYVGART SC in CIDP and ongoing studies for expanding indications. The announcement highlights Argenx’s strong market position and continued growth potential, with significant pipeline advancements and strategic collaborations to enhance its discovery capabilities.